Investors

Investor Presentation July 2020

2020 Annual General Meeting

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc Announces Appointment of John H. Johnson to Chief Executive Officer

07/07/20

DUBLIN, Ireland and TREVOSE, Pa. , July 07, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that at...

Read More
Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome

07/01/20

Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020 DUBLIN, Ireland and TREVOSE, Pa. , July 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc Announces Appointment of John H. Johnson to Chief Executive Officer

Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome

Upcoming Events